RNA Interference-Mediated Validation of Survivin and Apollon/BRUCE as New Therapeutic Targets for Cancer Therapy

2012 ◽  
Vol 12 (2) ◽  
pp. 69-78 ◽  
Author(s):  
Marzia Pennati ◽  
Enrico Millo ◽  
Paolo Gandellini ◽  
Marco Folini ◽  
Nadia Zaffaroni
Keyword(s):  
Rna Interference ◽  
Cancer Therapy ◽  
Therapeutic Targets ◽  
New Therapeutic Targets

scholarly journals PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemia

2012 ◽  
Vol 10 (4) ◽  
pp. 526-527
Author(s):  
Carlos Eduardo dos Santos Ferreira ◽  
Francisco Antônio Helfenstein Fonseca ◽  
Cristóvão Luis Pitangueira Mangueira
Keyword(s):  
Rna Interference ◽  
Treatment Adherence ◽  
Therapeutic Targets ◽  
Clinical Importance ◽  
Secondary Prophylaxis ◽  
Blood Cholesterol ◽  
New Therapeutic Targets ◽  
Remarkable Progress

This is a remarkable progress; since the finding of statins, there was no new way of reducing, significantly, cholesterol and LDL fraction. It is also clear that this decrease, by statins, is related to future cardiovascular lesions, being useful in its primary and secondary prophylaxis. The authors presented studies on research to promote the falling of blood cholesterol by means of antibodies, which inhibit the pro-protein PCSK9, as well as agents that act performing the RNA interference. We had two advantages immediately: for patients with myopathy associated with statins, and the fact of being injected every 15 days, that may contribute to better treatment adherence.

Therapeutic Targets for the Treatment of Comorbidities Associated with Epilepsy

2020 ◽  
Vol 13 (2) ◽  
pp. 85-93
Author(s):  
Kinjal Gangar ◽  
Lokesh Kumar Bhatt
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Attention Deficit ◽  
Neurological Disorders ◽  
Therapeutic Targets ◽  
Therapeutic Failure ◽  
Hyperactivity Disorder ◽  
Novel Targets ◽  
New Therapeutic Targets ◽  
Dual Mechanism ◽  
Seizure Suppression

One of the most common neurological disorders, which occurs among 1% of the population worldwide, is epilepsy. Therapeutic failure is common with epilepsy and nearly about 30% of patients fall in this category. Seizure suppression should not be the only goal while treating epilepsy but associated comorbidities, which can further worsen the condition, should also be considered. Treatment of such comorbidities such as depression, anxiety, cognition, attention deficit hyperactivity disorder and, various other disorders which co-exist with epilepsy or are caused due to epilepsy should also be treated. Novel targets or the existing targets are needed to be explored for the dual mechanism which can suppress both the disease and the comorbidity. New therapeutic targets such as IDO, nNOS, PAR1, NF-κb are being explored for their role in epilepsy and various comorbidities. This review explores recent therapeutic targets for the treatment of comorbidities associated with epilepsy.

scholarly journals Melanin production in coelomycetous agents of black grain eumycetoma

2021 ◽  
Author(s):  
Wilson Lim ◽  
Florianne Parel ◽  
Sybren de Hoog ◽  
Annelies Verbon ◽  
Wendy W J van de Sande
Keyword(s):  
Fungal Infection ◽  
Therapeutic Targets ◽  
Biosynthetic Pathways ◽  
Melanin Synthesis ◽  
Melanin Production ◽  
Causative Agents ◽  
New Therapeutic Targets

Abstract Background Eumycetoma is a fungal infection characterised by the formation of black grains by causative agents. The melanin biosynthetic pathways used by the most common causative agents of black-grain mycetoma are unknown and unravelling them could identify potential new therapeutic targets. Method Melanin biosynthetic pathways in the causative fungi were identified by the use of specific melanin inhibitors. Results In Trematosphaeria grisea and Falciformispora tompkinsii, 1,8-dihydroxynaphthalene (DHN)-melanin synthesis was inhibited, while DHN-, 3,4-dihydroxyphenylalanine (DOPA)- and pyo-melanin were inhibited in Medicopsis romeroi and Falciformispora senegalensis. Conclusion Our data suggest that Me. romeroi and F. senegalensis synthesise DHN-, DOPA- and pyo-melanin, while T. grisea and F. tompkinsii only synthesise DHN-melanin.

Sign in / Sign up

Export Citation Format

Share Document